Citations

Clear

1320 citation(s) found for "Nguyen, Vi".

Single Cell Approaches Reveal Perturbed Brain Vascular Molecules in Alzheimer’s Disease
İş, Özkan , Wang, Xue , Reddy, Joseph S. , Min, Yuhao , Quicksall, Zachary , White, Launia J. , Deniz, Kaancan , Tutor‐New, Frederick Q, Carnwath, Troy , Oatman, Stephanie R., Carrasquillo, Minerva M. , Nguyen, Thuy , Petersen, Ronald C. , Allen, Mariet , Ertekin‐Taner, Nilüfer , Patel, Tulsi , Heckman, Michael G. , Kouri, Naomi , Carrasquillo, Minerva M. , Kantarci, Kejal , Nho, Kwangsik T. , Saykin, Andrew J. , Dickson, Dennis W. , Murray, Melissa E.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S4 | Pages: No page available

10.1002/alz.063202 Get It

AbstractBackgroundInter‐cellular communication within the gliovascular unit (GVU) is critical for cerebral blood flow regulation, maintenance of the blood‐brain‐barrier (BBB) properties, and brain energy metabolism. Although numerous cell biology studies demonstrate the role of the GVU for BBB breakdown in Alzheimer’s disease (AD), the precise molecular changes contributing to its pathophysiology are unclear.MethodWe performed single nucleus RNA sequencing (snRNAseq) of temporal cortex tissue in 24 AD and control brains to understand the transcriptional changes in the cells of GVU. We acquired the snRNAseq profile of 79,751 total brain cells that comprise 6,541 astrocytes and 2,210 vascular cells. The latter formed three distinct vascular clusters characterized as activated pericytes, endothelia and resting pericytes. We identified differentially expressed genes (DEGs) and their enriched pathways in these clusters and detected the most transcriptional changes within activated pericytes. Using our data and a knowledge‐based predictive algorithm, we discovered and prioritized molecular interactions between vascular and astrocyte clusters, the main cell types of the GVU of the BBB.ResultsVascular targets predicted to interact with astrocytic ligands have biological functions in signalling, angiogenesis, amyloid ß metabolism and cytoskeletal structure. Top astrocytic and vascular interacting molecules include both novel and known AD risk genes such as APOE, APP and ECE1. We validated gene expression changes using qPCR. We are in the process of evaluating these gene expression changes in antemortem blood from AD and control participants.ConclusionOur findings provide valuable information into the transcriptional changes in predicted vascular‐astrocytic partners at the GVU, highlighting insights into the molecular mechanisms of BBB breakdown in AD.
Intraoperative Ergonomic Assessment of Exoscopes versus Conventional DIEP Flap
Wang, Tianke , Nguyen, Minh-Doan T. , Harless, Christin A., Smith, Tianqi Gao, Norasi, Hamid , Nguyen, Minh-Doan, Harless, Christin, Smith, Tianqi G, Hallbeck, Susan, Law, Katherine E. , Tetteh, Emmanuel , Hallbeck, M. Susan

Mayo Clinic

Journal of Reconstructive Microsurgery | December 13, 2022 | Volume: 39 | Issue: 06 | Pages: 453-461

10.1055/s-0042-1758188 | PMID 36509101 Get It

Abstract Background This study compared the ergonomics of surgeons during deep inferior epigastric perforator (DIEP) flap surgery using either baseline equipment (loupes, headlights, and an operating microscope) or an exoscope. Plastic surgeons may be at high risk of musculoskeletal problems. Recent studies indicate that adopting an exoscope may significantly improve surgeon postures and ergonomics. Methods Postural exposures, using inertial measurement units at the neck, torso, and shoulders, were calculated in addition to the surgeons' subjective physical and cognitive workload. An ergonomic risk score on a scale of 1 (lowest) to 4 (highest) was calculated for each of the postures observed. Data from 23 bilateral DIEP flap surgeries (10 baseline and 13 exoscope) were collected. Results The neck and torso risk scores decreased significantly during abdominal flap harvest and chest dissection, while right shoulder risk scores increased during the abdominal flap harvest for exoscope DIEP flap procedures compared with. Exoscope anastomoses demonstrated higher neck, right shoulder, and left shoulder risk scores. The results from the survey for the “surgeon at abdomen” showed that the usage of exoscopes was associated with decreased performance and increased mental demand, temporal demand, and effort. However, the results from the “surgeon at chest” showed that the usage of exoscopes was associated with lower physical demand and fatigue, potentially due to differences in surgeon preference. Conclusion Our study revealed some objective evidence for the ergonomic benefits of exoscope; however, this is dependent on the tasks the surgeon is performing. Additionally, personal preferences may be an important factor to be considered in the ergonomic evaluation of the exoscope.
Impact of recurrent hospitalization for Clostridioides difficile on longitudinal outcomes in patients with inflammatory bowel diseases: a nationally representative cohort
Venkat, Preethi G., Nguyen, Nghia , Luo, Jiyu , Qian, Alexander S. , Khanna, Sahil , Singh, Siddharth

Mayo Clinic

Therapeutic Advances in Gastroenterology | December 8, 2022 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/17562848221141501 | PMID 36518884 Get It

Background: Clostridioides difficile infection (CDI) is associated with poor outcomes in patients with inflammatory bowel diseases (IBD). Objectives: We conducted a nationally representative cohort study to evaluate the impact of recurrent CDI (rCDI)-related hospitalization on longitudinal unplanned healthcare utilization in patients with IBD. Design: This was a retrospective cohort study that utilized the 2017 Nationwide Readmissions Database (NRD). Methods: We identified 13,446 patients with IBD, hospitalized at least twice from January to June 2017 and followed through December 2017; of these, 1,148 had CDI-related hospitalizations. We compared the annual burden of hospitalization and IBD-related surgery in IBD patients with rCDI-related admission versus single CDI-related admission (primary reference), and those with one or more CDI-related admission versus no CDI-related admission (secondary reference). Results: There were no significant differences in risk and burden of unplanned healthcare utilization (time spent in-hospital, 27 days versus 27 days, p = 0.62), 6-month readmission (63% versus 64.3%, p = 0.8) or IBD-related surgery in patients with recurrent (two or more) CDI-related hospitalizations versus single CDI-related admission. However, patients with ⩾1 CDI-related admission versus no CDI admissions experienced higher rate of 6-month readmission (61.1% versus 55.7%, p<.001), total days spent in the hospital per year (median: 26 days versus 21 days, p<.001), total cost across all hospitalizations per year ($212,524 versus $184,384, p < 0.01), and inpatient mortality (3.28% versus 1.81%, p = 0.01), without an increase in risk of IBD-related surgery (6.7% versus 6.4%, p = 0.79). Conclusion: While patients with IBD hospitalized for CDI have poor longitudinal inpatient outcomes, recurrent admissions for CDI may not increase risk of adverse outcomes compared to one-time admission.
Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor–Positive Breast Cancer
Wei, Lixuan , Gao, Huanyao , Yu, Jia , Zhang, Huan , Nguyen, Thanh Thanh L. , Gu, Yayun , Passow, Marie R. , Carter, Jodi M. , Qin, Bo , Boughey, Judy C. , Weinshilboum, Richard M. , Wang, Liewei , Boughey, JC , Goetz, Matthew P , Weinshilboum, Richard M. , Ingle, J , Wang, Liewei , Nguyen, Thanh Thanh L. , Carter, Jodi , Goetz, Matthew P. , Ingle, James N.

Mayo Clinic

Cancer Research | December 5, 2022 | Volume: 83 | Issue: 3 | Pages: 456-470

10.1158/0008-5472.can-22-1016 | PMID 36469363 Get It

Abstract Androgen receptor (AR) is expressed in 80% to 90% of estrogen receptor α–positive (ER+) breast cancers. Accumulated evidence has shown that AR is a tumor suppressor and that its expression is associated with improved prognosis in ER+ breast cancer. However, both a selective AR agonist (RAD140) and an AR inhibitor (enzalutamide, ENZ) have shown a therapeutic effect on ER+ breast cancer, so the potential for clinical application of AR-targeting therapy for ER+ breast cancer is still in dispute. In this study, we evaluated the efficacy of ENZ and RAD140 in vivo and in vitro in AR+/ER+ breast cancer models, characterizing the relationship of AR and ER levels to response to AR-targeting drugs and investigating the alterations of global gene expression and chromatin binding of AR and ERα after ENZ treatment. In the AR-low setting, ENZ directly functioned as an ERα antagonist. Cell growth inhibition by ENZ in breast cancer with low AR expression was independent of AR and instead dependent on ER. In AR-high breast cancer models, AR repressed ERα signaling and ENZ promoted ERα signaling by antagonizing AR. In contrast, RAD140 activated AR signaling and suppressed AR-high tumor growth by deregulating ERα expression and blocking ERα function. Overall, analysis of the dynamic efficacies and outcomes of AR agonist, and antagonist in the presence of different AR and ERα levels reveals regulators of response and supports the clinical investigation of ENZ in selected ER+ tumors with a low AR/ER ratio and AR agonists in tumors with a high AR/ER ratio. Significance: The ratio of androgen receptor to estrogen receptor in breast cancer dictates the response to AR-targeted therapies, providing guidelines for developing AR-directed treatment strategies for patients with breast cancer.
TDP‐43 pathology effect on volume and flortaucipir uptake in Alzheimer's disease
Carlos, Arenn F. , Tosakulwong, Nirubol , Weigand, Stephen D. , Petersen, Ronald C. , Nguyen, Aivi T. , Reichard, R. Ross , Lowe, Val J. , Whitwell, Jennifer L. , Josephs, Keith A. , Nguyen, Aivi T , Carlos, Arenn F , Senjem, Matthew L. , Schwarz, Christopher G. , Knopman, David S. , Boeve, Bradley F. , Dickson, Dennis W. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | December 4, 2022 | Volume: 19 | Issue: 6 | Pages: 2343-2354

10.1002/alz.12878 | PMID 36463537 Get It

AbstractIntroductionAlzheimer's disease (AD) patients ≥70 years show smaller medial temporal volumes despite less 18F‐flortaucipir‐positron emission tomography (PET) uptake than younger counterparts. We investigated whether TAR DNA‐binding protein 43 (TDP‐43) was contributing to this volume‐uptake mismatch.MethodsSeventy‐seven participants with flortaucipir‐PET and volumetric magnetic resonance imaging underwent postmortem AD and TDP‐43 pathology assessments. Bivariate‐response linear regression estimated the effect of age and TDP‐43 pathology on volume and/or flortaucipir standardized uptake volume ratios of the hippocampus, amygdala, entorhinal, inferior temporal, and midfrontal cortices.ResultsOlder participants had lower hippocampal volumes and overall flortaucipir uptake. TDP‐43‐immunoreactivity correlated with reduced medial temporal volumes but was unrelated to flortaucipir uptake. TDP‐43 effect size was consistent across the age spectrum. However, at older ages, the cohort mean volumes moved toward those of TDP‐43‐positives, reflecting the increasing TDP‐43 pathology frequency with age.DiscussionTDP‐43 pathology is a relevant contributor driving the volume‐uptake mismatch in older AD participants.Highlights TDP‐43 pathology affects medial temporal volume loss but not tau radiotracer uptake. Greater TDP‐43 pathology effect is seen in old age due to its increasing frequency. TDP‐43 pathology is a relevant driver of the volume‐uptake mismatch in old AD patients.
Prognostic Variables in Male Breast Cancer
Clark, John L. , Jaszcz, W, Jatoi, Aminah , Niehans, Gloria A., Nguyen, Phuong

Mayo Clinic

The American Surgeon | November 29, 2022 | Volume: 66 | Issue: 5 | Pages: 502-511

10.1177/000313480006600515 Get It

The prognostic role of ploidy status, S phase fraction, estrogen and progesterone receptor status, and the expression of p53 and erbB-2 protein in male breast carcinoma (MBC) remains controversial. The primary objective of this study was to determine which of the common prognostic factors for female breast cancer predict prognosis in MBC. A secondary objective was to assess the impact of comorbid illnesses on survival. A retrospective review of demographic data, surgical treatment, pathological staging, adjuvant treatment and follow-up was completed for 16 patients with MBC (1 intraductal and 15 invasive). Formalin-fixed, paraffin-embedded tissue was processed for ploidy, S phase fraction, and immunohistochemical detection of estrogen and progesterone receptors plus expression of p53 and erbB-2 protein. Six of 15 patients with infiltrating ductal carcinoma are currently alive without evidence of disease and a median survival of 61 months. Nine patients died after a median survival of 52 months, with 6 patients having no evidence of recurrent breast cancer. Two of 3 deaths secondary to advanced breast cancer occurred in patients who initially presented with T 4 lesions and were staged IIIB. Two of 15 tumors were erbB-2 positive, whereas only 1 tested weakly positive for p53 protein. We observed that MBCs express erbB-2 and p53 proteins infrequently. Neither ploidy status, S phase fraction, nor erbB-2/ p53 status provided any apparent improvement in establishing prognosis beyond routine pathological staging. Advanced TNM stage was associated with diminished survival. The majority of MBCs express estrogen and progesterone receptors. Survivals in MBC were reduced in association with comorbid medical conditions.
A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies
Samaniego, Felipe , Sadiq, Ahad A., Mahadevan, Daruka , Koontz, Michael Zach, Burke, John M. , Cherry, Mohamad , Melear, Jason M., Priego, Victor, Cobb, Patrick , Cull, Elizabeth H., Conkling, Paul , Cosgrove, David , Haney, Donna Nguyen, Hu, Jia, Rice, William G. , Bejar, Rafael, Villasboas, José C. , Reid, Erin G , Roeker, Lindsey E. , Sinha, Ranjeet Kumar , Bejar, Rafael

Mayo Clinic

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6498-6500

10.1182/blood-2022-163683 Get It

Mediterranean Diet Intervention in Patients with Myeloproliferative Neoplasm
Mendez, Laura F., Li, Jiarui , Nguyen, Jenny , Nguyen, Hellen , Scherber, Robyn M. , Avelar‐Barragan, Julio , Kosiorek, Heidi , Mesa, Ruben A. , Whiteson, Katrine , Odegaard, Andrew , Fleischman, Angela G.

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3972-3973

10.1182/blood-2022-168865 Get It